Vol. 8, Issue 8 (2019)

Early detection of signals from both clinical trials and post marketing surveillance studies have now been adapted by major pharmaceutical companies in order to identify the risks associated with the medicinal product and effectively manage the risks by applying robust risk management plans throughout the life cycle of the product. Signal detection and risk management have added a new dimension to the field of pharmacovigilance, an evolving discipline; it requires ongoing refinement in order to increase its applicability and value to public health. There is an immense need to understand the importance of pharmacovigilance and how it impacts the life cycle of the product. This will enable integration of good pharmacovigilance practice in the processes and procedures to help ensure regulatory compliance and enhance clinical trial safety and post-marketing surveillance (Gildeeva, 2016).

Surveillance system is to ensure the safety of veterinary medicines once they are authorized and being used in the market place (Saygi, 2016). The rapid identification of any adverse effects to medicines is essential and the data produced from the investigation should be assessed in order to reduce risks in the future use of the product (Das et al., 2014).